Incidence and risk factors of HIV-related non-Hodgkins lymphoma in the era of combination antiretroviral therapy: a European multicohort study.Reportar como inadecuado

Incidence and risk factors of HIV-related non-Hodgkins lymphoma in the era of combination antiretroviral therapy: a European multicohort study. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

* Corresponding author 1 ISPM - Institute of Social and Preventive Medicine 2 Epidémiologie Clinique et Traitement de l-Infection à VIH 3 Department of Internal Medicine 4 Department of Social Medicine 5 Centro Nacional de Epidemiología 6 Department of primary care and population sciences 7 CISIH - Centre d-Information et de Soins de l-Immunodéficience Humaine 8 IACR - International Agency for Cancer Research 9 2nd Blood Transfusion and Hemophilia Center 10 Infectious Diseases Service 11 Copenhagen HIV Programme 12 ISPED - Institut de Santé Publique, d-Epidémiologie et de Développement

Abstract : BACKGROUND: Incidence and risk factors of HIV-associated non-Hodgkin-s lymphoma NHL are not well defined in the era of combination antiretroviral therapy cART. METHODS: A total of 56,305 adult HIV type-1 HIV-1-infected patients who started cART in 1 of 22 prospective studies in Europe were included. Weibull random effects models were used to estimate hazard ratios HRs for developing systemic NHL and included CD4+ T-cell counts and viral load as time-updated variables. RESULTS: During the 212,042 person-years of follow-up, 521 patients were diagnosed with systemic NHL and 62 with primary brain lymphoma PBL. The incidence rate of systemic NHL was 463 per 100,000 person-years not on cART and 205 per 100,000 person-years in treated patients for a rate ratio of 0.44 95% confidence interval CI 0.37-0.53. The corresponding incidence rates of PBL were 57 and 24 per 100,000 person-years rate ratio 0.43, 95% CI 0.25-0.73. Suppression of HIV-1 replication on cART HR 0.60, 95% CI 0.44-0.81, comparing < or =500 with 10,000-99,999 copies-ml and increases in CD4+ T-cell counts HR 0.30, 0.22-0.42, comparing > or =350 with 100-199 cells-microl were protective; a history of Kaposi-s sarcoma HR 1.70, 1.08-2.68, compared to no history of AIDS, transmission through sex between men HR 1.57, 1.19-2.08, compared with heterosexual transmission and older age HR 3.71, 2.37-5.80, comparing > or =50 with 16-29 years were risk factors for systemic NHL. CONCLUSIONS: The incidence rates of both systemic NHL and PBL were substantially reduced in patients on cART. Timely initiation of therapy is key to the prevention of NHL in the era of cART.

Keywords : non-Hodgkin lymphoma cohort studies antiretroviral therapy Kaposi sarcoma immunodeficiency viral load Europe

Autor: Julia Bohlius - Kurt Schmidlin - Dominique Costagliola - Gerd Fätkenheuer - Margaret May - Ana Maria Caro-Murillo - Amanda Mocro



Documentos relacionados